Polyphosphokinase mutant as well as coding gene, plasmid, genetically engineered bacterium and application thereof

By introducing high-performance polyphosphate kinase mutants and fermentation medium formula adjustment, the problem of L-glutamate residue in L-glutamine production in microbial fermentation is solved, which improves yield and purification efficiency and reduces production costs.

CN119020315APending Publication Date: 2024-11-26SHIJIAZHUANG UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411151768.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-21
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

During the microbial fermentation and production of L-glutamine, the problem of L-glutamate residue leads to high impurity content in the product and difficulty in separation and purification. The prior art is difficult to effectively reduce the L-glutamate impurity content, affecting the yield and product quality.

Method used

By introducing directionally evolved high-performance polyphosphate kinase mutants, the efficiency of ATP supply is improved, the synthesis reaction of ATP and L-glutamate is promoted, and the formulation adjustment of fermentation medium is adjusted to reduce the content of L-glutamate impurities and improve L -Glutamine yield.

Benefits of technology

The production of L-glutamine has been increased to 98.3g/L, and the L-glutamic acid impurities have been reduced by more than 60%, reducing production costs and purification difficulties, and is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005003845900000081
    Figure BDA0005003845900000081
  • Figure BDA0005003845900000091
    Figure BDA0005003845900000091
  • Figure BDA0005003845900000101
    Figure BDA0005003845900000101
Patent Text Reader

Abstract

The invention belongs to the technical field of bioengineering, and particularly relates to a polyphosphate kinase mutant as well as a coding gene, a plasmid, a genetically engineered bacterium and application thereof. The polyphosphokinase mutant is obtained by mutating alanine at the 93rd site or isoleucine at the 152nd site of a sequence as shown in an amino acid sequence SEQ ID NO.1 into other amino acids. When the coding gene, plasmid and genetically engineered bacteria of the high-performance polyphosphate kinase mutant subjected to directed evolution are used for fermentation production of L-glutamine, the ATP supply efficiency in a system can be improved, the synthetic reaction of ATP and a substrate L-glutamic acid is promoted, and the content of the impurity L-glutamic acid is reduced. And by combining the formula regulation and control of the fermentation culture medium, the L-glutamic acid impurities are further reduced, and the yield of L-glutamine is increased. The method can be used in the process of producing L-glutamine through microbial fermentation, and is simple to operate, high in reaction efficiency and suitable for industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of bioengineering, and in particular to a polyphosphate kinase mutant and its encoding gene, plasmid, genetic engineering bacteria and application. Background Art

[0002] L-glutamine (L-glutamine, L-Gln) is an important natural amino acid, plays an important role in organisms, and belongs to semi-essential amino acids. In recent years, L-glutamine, as an important nutrient in animal cell culture medium, promotes cell proliferation and differentiation, and is the raw material for animal and plant cell culture to produce new macromolecular drugs and vaccines. The synthesis method of L-glutamine includes chemical method, enzyme method and fermentation method, and direct fermentation method is the main method in actual production. At present, the production of L-glutamine by Corynebacterium glutamicum fermentation method is its mainstream production method, as disclosed in Chinese patents such as publication number CN105349590B and CN104404097B.

[0003] When transforming Corynebacterium glutamicum that produces L-glutamine, researchers have used various means to enhance the ability of L-glutamine synthetase (GS) to increase the yield of L-glutamine. For example, Chinese patents with publication numbers CN1250716C, CN1316011C, CN114277003A, and CN114277003B disclose this. In addition, there are many successful examples of metabolic pathway modification using methods such as gene knockout, including Chinese patents with publication number CN113684165B, etc. The yield of L-glutamine obtained varies, but is generally below 90g / L, and there is still a need to further increase the yield.

[0004] Although the production of L-glutamine by microbial fermentation is more suitable from a cost perspective, when L-glutamine is produced by fermentation, the precursor of the metabolic pathway is L-glutamic acid. If the GS enzyme reaction is incomplete and the GS activity is insufficient, a certain amount of L-glutamic acid will remain in the fermentation system, resulting in the current shortcomings of high impurity content in the fermentation product and difficulty in separating and purifying L-glutamine. As stated in the "Progress in the Production of L-Glutamine by Fermentation" published by Tang Yajie et al. in the Journal of Food Science, the main by-product of the L-glutamine fermentation process is glutamic acid, and L-glutamine and glutamic acid have similar molecular structures and chemical properties and are difficult to separate. The current public laboratory extraction yield can reach 70%. However, at the end of the fermentation of L-glutamine by microbial fermentation, it is generally required to control L-glutamic acid below 0.5%. A lower L-glutamic acid content is conducive to improving the quality of the product L-glutamine. Therefore, how to solve the problem of L-glutamic acid residues in the production of L-glutamine by microbial fermentation remains to be solved. Summary of the invention

[0005] The purpose of the present invention is to provide a polyphosphate kinase mutant and the encoding gene, plasmid, genetic engineering bacteria and application of the mutant. By utilizing the encoding gene of the polyphosphate kinase mutant, the corresponding plasmid and the transformed genetic engineering bacteria are constructed to solve the problem of improving the yield of L-glutamine produced by microbial fermentation and reducing the residual L-glutamic acid. The present invention introduces the high-performance polyphosphate kinase after directed evolution into the L-glutamine fermentation strain, and promotes the synthesis reaction of ATP and substrate L-glutamic acid by improving the ATP supply efficiency in the system, thereby reducing the impurity L-glutamic acid content. Combined with the adjustment and control of the fermentation medium formula, the purpose of reducing L-glutamic acid impurities is further achieved, while increasing the yield of L-glutamine.

[0006] In order to achieve the above object, the technical solution adopted by the present invention is:

[0007] A polyphosphate kinase mutant, based on the amino acid sequence shown in SEQ ID NO.1, the 93rd alanine or the 152nd isoleucine is mutated to other amino acids.

[0008] The amino acid sequence of the wild-type polyphosphate kinase encoded by the polyphosphate kinase gene ppk2 from Bacillota bacterium is 298 aa in length, and the sequence is as shown in SEQ ID NO.1:

[0009] MINIYKIDKLNNFNLNNHKTDDYSLCKDKDTALELTQKNIQKIYDYQQKLYAEKKEGLIIAFQAMDAAGKDGTIREVLKALAPQGVHEKPFKAPSSTELAHDYLWRVHNAVPEKGEITIFNRSHYEDVLIGKVKELYKFQNKADRIDENTVIDNRYEDIRNFEKYLYNNSVRIIKIFLNVSKKEQAERFLSRIEEPEKNWKFSDSDFEERVYWDKYQQAFEDAINATSTKDCPWYVVPADRKWYMRYVVSEIVVKTLEEMNPKYPTVTKETLERFEGYRTKLLEEYNYDLDTIRPIEK

[0010] The nucleotide sequence corresponding to SEQ ID NO.1, with a length of 897 bp, as shown in SEQ ID NO.2:

[0011] ATGATTAACATTTATAAAATTGATAAACTGAACAACTTTAACCTGAACAACCATAAAACCGATGATTATAGCCTGTGCAAAGATAAAGATACCGCGCTGGAACTGACGCAGAAAAACATTCAGAAAATTTATGATTATCAGCAGAAACTGTATGCGGAAAAAAAAGAAGGCCTGATTATTGCGTTTCAAGCGATGGATGCGGCGGGCAAAGATGGCACCATTCGCGAAGTGCTGAAAGCGCTGGCGCCGCAAGGCGTGCATGAAAAACCGTTTAAAGCGCCGAGCAGCACCGAACTGGCGCATGATTATCTGTGGCGCGTGCATAACGCGGTGCCGGAAAAAGGCGAAATTACCATTTTTAACCGCAGCCATTATGAAGATGTGCTGATTGGCAAAGTGAAAGAACTGTATAAATTTCAGAACAAAGCGGATCGCATTGATGAAAACACCGTGATTGATAACCGCTATGAAGATATTCGCAACTTTGAAAAATATCTGTATAACAACAGCGTGCGCATTATTAAAATTTTTCTGAACGTGAGCAAAAAAGAACAAGCGGAACGCTTTCTGAGCCGCATTGAAGAACCGGAAAAAAACTGGAAATTTAGCGATAGCGATTTTGAAGAACGCGTGTATTGGGATAAATATCAGCAAGCGTTTGAAGATGCGATTAACGCGACGAGCACCAAAGATTGCCCGTGGTATGTGGTGCCGGCGGATCGCAAATGGTATATGCGCTATGTGGTGAGCGAAATTGTGGTGAAAACCCTGGAAGAAATGAACCCGAAATATCCGACCGTGACCAAAGAAACCCTGGAACGCTTTGAAGGCTATCGCACCAAACTGCTGGAAGAATATAACTATGATCTGGATACCATTCGCCCGATTGAAAAATAA

[0012] As a limitation of the present invention, based on the amino acid sequence as shown in SEQ ID NO.1, the 93rd alanine is mutated to threonine, cysteine ​​or serine; or the 152nd isoleucine is mutated to glycine or valine.

[0013] The present invention also provides a coding gene, wherein the coding gene encodes any one of the polyphosphate kinase mutants described above.

[0014] As a limitation of the present invention, the gene is expressed in the form of episomal overexpression or genomic integration.

[0015] The present invention also provides a plasmid, which carries the coding gene of the polyphosphate kinase mutant.

[0016] As a limitation of the present invention, the expression mode of the gene carried by the above-mentioned plasmid is free overexpression or other genome integration plasmids are used for genome integration.

[0017] As a further limitation, the episomal overexpression vector is pXMJ19.

[0018] The present invention also provides a genetically engineered bacterium, which uses Corynebacterium glutamicum as a host and expresses a coding gene of a polyphosphate kinase mutant through free overexpression or genome integration.

[0019] The present invention also provides the application of the genetically engineered bacteria in L-glutamine fermentation production.

[0020] As a further limitation of the present invention, the fermentation culture time of the fermentation production is 45-60 hours, and the inoculation amount is 10%-20% by volume.

[0021] The present invention also provides a fermentation production method of L-glutamine, wherein the genetically engineered bacteria used for fermentation production contain the above-mentioned coding gene, and the culture medium used includes a fermentation culture medium and a culture medium feed, wherein the fermentation culture medium contains: KH2PO4 1-5g / L, MgSO4·7H2O 0.1-1g / L, MnSO4·H2O 2-20mg / L, ZnSO4·7H2O 0.1-2mg / L, CuSO4·5H2O 0.1-2mg / L, V B10.1-2mg / L, corn slurry 1-20g / L, glucose 80-200g / L, ATP 0.1-1g / L, (NaPO3) 65-25g / L, (NH4)2SO440-120g / L and CaCO310-100g / L; the pH value is regulated at 6.8-7.0 by ammonia water; the culture medium feed contains nitrogen source mixed feed and carbon source feed; the nitrogen source mixed feed contains: corn slurry 10-50g / L, K2HPO410-40g / L, MgSO41-5g / L, (NH4)2SO450-150g / L, ATP 0.01-0.2g / L and (NaPO3) 65-15g / L; the carbon source feed is 50-80% glucose by volume.

[0022] Due to the adoption of the above technical solution, the present invention has the following technical advances compared with the prior art:

[0023] (1) The present invention introduces high-performance polyphosphate kinase after directed evolution into L-glutamine fermentation strains, and by improving the ATP supply efficiency in the system, promotes the synthesis reaction of ATP and substrate L-glutamate, increases the yield of L-glutamine, and reduces the content of impurity L-glutamate. Compared with the existing production technology, the yield of L-glutamine in the 5L system can reach up to 98.3g / L, and the L-glutamate impurity can be reduced by more than 60%, with a minimum of 0.22%. The present invention reduces the production cost and purification difficulty of L-glutamine, improves the reaction efficiency, and is more suitable for industrial production.

[0024] (2) When the polyphosphate kinase mutant provided by the present invention is used to ferment and produce L-glutamine, the L-glutamic acid impurities can be further reduced by adjusting and controlling the fermentation medium formula, while increasing the yield of L-glutamine. The fermentation regulation method is simple to operate and is suitable for industrial production.

[0025] (3) When Corynebacterium glutamicum is used as a host, the genetically engineered bacteria obtained by constructing corresponding plasmids and expressing the coding gene of polyphosphate kinase mutants in a free overexpression or genome-integrated manner have good performance in the application of microbial fermentation to produce L-glutamine.

[0026] The present invention is further described in detail below in conjunction with specific embodiments. DETAILED DESCRIPTION

[0027] The present invention is further described in detail below by specific examples. It should be understood that the described examples are only used to explain the present invention, and are not intended to limit the present invention.

[0028] Unless otherwise specified, the materials and reagents used in the examples of the present invention can be obtained from commercial sources. Experimental methods without specific conditions in the examples are usually carried out under conventional conditions or under conditions recommended by the manufacturer.

[0029] The molecular biology experimental operations in the examples, including plasmid construction, culture medium preparation, etc., were mainly performed with reference to Molecular Cloning Experiment Guide (3rd edition), edited by J. Sambrook and DW Russell (USA), translated by Huang Peitang et al., Science Press, Beijing, 2002).

[0030] In the present invention, the mutants are represented by amino acids substituted at the original amino acid positions, wherein the position numbers correspond to the amino acid sequence positions of the polyphosphate kinase mutants.

[0031] Example 1 Polyphosphate kinase mutant in which alanine at position 93 is mutated to threonine

[0032] This embodiment is a polyphosphate kinase mutant pPK2-A93T, which is obtained by directional screening after random mutation. Compared with the amino acid sequence SEQ ID NO.1 of the wild-type polyphosphate kinase from Bacillota bacterium, the amino acid at position 93 in the amino acid sequence of the polyphosphate kinase mutant pPK2-A93T is mutated from alanine in the wild type to threonine, and the amino acid sequence of the obtained polyphosphate kinase mutant pPK2-A93T is shown in SEQ ID NO.3, and the nucleotide sequence is shown in SEQ ID NO.4.

[0033] SEQ ID NO.3:

[0034] MINIYKIDKLNNFNLNNHKTDDYSLCKDKDTALELTQKNIQKIYDYQQKLYAEKKEGLIIAFQAMDAAGKDGTIREVLKALAPQGVHEKPFKTPSSTELAHDYLWRVHNAVPEKGEITIFNRSHYEDVLIGKVKELYKFQNKADRIDEN TVIDNRYEDIRNFEKYLYNNSVRIIKIFLNVSKKEQAERFLSRIEEPEKNWKFSDSDFEERVYWDKYQQAFEDAINATSTKDCPWYVVPADRKWYMRYVVSEIVVKTLEEMNPKYPTVTKETLERFEGYRTKLLEEYNYDLDTIRPIEK

[0035] SEQ ID NO.4:

[0036] ATGATTAACATTTATAAAATTGATAAACTGAACAACTTTAACCTGAACAACCATAAAACCGATGATTATAGCCTGTGCAAAGATAAAGATACCGCGCTGGAACTGACGCAGAAAAACATTCAGAAAATTTATGATTATCAGCAGAAACTGTATGCGGAAAAAAAAAGGCCTGATTATTGCGTTTCAAGCGATGGATGCGGCGGGCAAAGATGGCACCATTCG CGAAGTGCTGAAAGCGCTGGCGCCGCAAGGCGTGCATGAAAAACCGTTTAAAACGCCGAGCAGCACCGAACTGGCGCATGATTATCTGTGGCGCGTGCATAACGCGGTGCCGGAAAAAGGCGAAATTACCATTTTTAACCGCAGCCATTATGAAGATGTGCTGATTGGCAAAGTGAAAGAACTGTATAAATTTCAGAACAAAGCGGATCGCATTGATGAAAACA CCGTGATTGATAACCGCTATGAAGATATTCGCAACTTTGAAAAATATCTGTATAACAACAGCGTGCGCATTATTAAAATTTTTCTGAACGTGAGCAAAAAAGAACAAGCGGAACGCTTTCTGAGCCGCATTGAAGAACCGGAAAAAAACTGGAAATTTAGCGATAGCGATTTTGAAGAACGCGTGTATTGGGATAAATATCAGCAAGCGTTTGAAGATGCGATT AACGCGACGAGCACCAAAGATTGCCCGTGGTATGGTGGTGCCGGCGGATCGCAAATGGTATATGCGCTATGTGGTGAGCGAAATTGTGGTGAAAACCCTGGAAGAAATGAACCCGAAATATCCGACCGTGACCAAAGAAACCCTGGAACGCTTTGAAGGCTATCGCACCAAACTGCTGGAAGAATATAACTATGATCTGGATACCATTCGCCCGATTGAAAAATAA

[0037] Example 2 Polyphosphate kinase mutant in which alanine at position 93 is mutated to cysteine

[0038] This embodiment provides a polyphosphate kinase mutant ppk2-A93C, which is obtained by directional screening after random mutation. Compared with the amino acid sequence SEQ ID NO.1 of the wild-type polyphosphate kinase from Bacillota bacterium, the amino acid at position 93 in the amino acid sequence of the polyphosphate kinase mutant ppk2-A93C is mutated from alanine in the wild type to cysteine.

[0039] Example 3 Polyphosphate kinase mutant in which alanine at position 93 is mutated to serine

[0040] This embodiment provides a polyphosphate kinase mutant ppk2-A93S, which is obtained by directional screening after random mutation. Compared with the amino acid sequence SEQ ID NO.1 of the wild-type polyphosphate kinase from Bacillota bacterium, the amino acid at position 93 in the amino acid sequence of the polyphosphate kinase mutant ppk2-A93S is mutated from alanine in the wild type to serine.

[0041] Example 4 Polyphosphate kinase mutant in which isoleucine at position 152 is mutated to glycine

[0042] This embodiment provides a polyphosphate kinase mutant ppk2-I152G, which is obtained by directional screening after random mutation. Compared with the amino acid sequence SEQ ID NO.1 of the wild-type polyphosphate kinase from Bacillota bacterium, the amino acid at position 152 in the amino acid sequence of the polyphosphate kinase mutant ppk2-I152G is mutated from isoleucine in the wild type to glycine.

[0043] Example 5 Polyphosphate kinase mutant in which isoleucine at position 152 is mutated to valine

[0044] This embodiment provides a polyphosphate kinase mutant ppk2-I152V, which is obtained by directional screening after random mutagenesis. Compared with the amino acid sequence SEQ ID NO.1 of the wild-type polyphosphate kinase from Bacillota bacterium, the amino acid at position 152 in the amino acid sequence of the polyphosphate kinase mutant ppk2-I152V is mutated from isoleucine in the wild type to valine.

[0045] In other embodiments, the polyphosphate kinase mutant is a mutant in which the 93rd alanine or the 152nd isoleucine in the amino acid sequence shown in SEQ ID NO.1 is mutated to other amino acids.

[0046] Example 6 A gene encoding a polyphosphate kinase mutant, a recombinant plasmid carrying the gene, and a genetically engineered bacterium

[0047] (I) Obtaining plasmid and mutation template

[0048] Using the nucleotide sequence of the polyphosphate kinase gene ppk2 from Bacillota bacterium (preliminary screening of the sequence of Polyphosphate kinase 2familyprotein (NCBI SequenceID: MDI9519035.1) with good ATP cycle ability) as a template, the primers shown in Table 1 were designed, constructed and expressed, and further optimized. The sequence was cloned into the pET29a expression frame by homologous recombination.

[0049] The process of homologous recombination is as follows:

[0050] (i) Using primers 29PDF and 29PDR, the target fragment was obtained by PCR:

[0051] The PCR system was 50 μL, 25 μL of 2xTaqmix, 1 μL (10 pm / μL) of primers 29PDF and 29PDR, 1 μL (40 μg / μL) of template DNA (ppk2), and the remaining volume was filled with water.

[0052] The PCR program was set as follows: 95°C for 10 min, 95°C for 1 min + 55°C for 30 s + 72°C for 5 min, 30 cycles, 72°C for 1 min. The target fragment was obtained by PCR.

[0053] (ii) Using primers 29ZTF and 29ZTR, obtain the vector fragment by PCR:

[0054] The PCR system was 50 μL, 2xTaqmix 25 μL, primers 29ZTF and 29ZTR 1 μL each (10 pm / μL), template DNA (pET29a) 1 μL (40 μg / μL), and the remaining volume was filled with water.

[0055] The PCR program was set as follows: 95°C for 10 min, 95°C for 1 min + 55°C for 30 s + 72°C for 5 min, 30 cycles, and 72°C for 6 min. The vector fragment was obtained by PCR.

[0056] (iii) Take 5 μL of buffer, and the target fragment and vector fragment in a mass ratio of 1:2, mix them to obtain a total of 10 μL of homologous recombination system, and construct a plasmid. After homologous recombination sequencing is correct, the plasmid is named pET29a-ppk2.

[0057] The plasmid and the strain containing the plasmid were used as mutation templates for mutant screening. The strain containing the plasmid was used as a wild-type test control strain for vitality determination.

[0058] Table 1 Primer design

[0059]

[0060]

[0061] (II) Screening of mutation positions of polyphosphate kinase mutants and activity detection

[0062] The mutation position was screened by random mutation. According to the results of nearly 100 strains, the plasmids of strains with obvious changes in ATP synthesis ability were extracted and sequenced to determine the position. It was found that the activity changed greatly after the two positions A93 and I152 were changed, especially the A93 position. Subsequently, a rational design method was used to design mutation sites for pET29a-ppk2. The test sites were selected as saturated mutations at the A93 and I152 positions. The ATP generation activity was determined using the same method. Except for mutations with no obvious change in activity and mutations with significantly decreased activity, there were 5 mutations with significantly increased activity. The enzyme solutions of these 5 single mutations were treated at 45°C for 10 minutes, and the activity was measured again to evaluate the stability of the mutated protein.

[0063] The specific enzyme solution preparation method is as follows:

[0064] The expression strain containing the pET29a-ppk2 plasmid and the mutant strain to be tested were inoculated into LB medium with a final Kan concentration of 50 mg / L, wherein the LB liquid medium contained: peptone 10 g / L, yeast extract 5 g / L, NaCl 10 g / L; the inoculation amount was 2% by volume, and the culture was shaken at 37°C and 200 rpm. The bacterial density OD 600 When the concentration is about 0.6-0.8, add IPTG with a final concentration of 0.2mM. Induce at 20℃ for 18 hours, collect the cells after centrifugation at 6000rpm for 10 minutes, concentrate and resuspend to 100g / L using 20mM-Tris-HCl buffer with pH 6.5 as the breaking buffer, and ultrasonically break at 4℃; centrifuge at 12000rpm for 10min, collect the supernatant, identify the expression by SDS-PAGE and determine the ATP activity after corresponding dilution.

[0065] The specific method of vitality test is as follows:

[0066] In 1 mL of the reaction system, pH 7.0, a final concentration of 50 mM nucleotide 5' adenosine monophosphate sodium salt (C 10 H 12N5O7PXNa2+YH2O), 50mM (NaPO3)6, 50mM MgCl2·6H2O and 100μL of enzyme solution with different dilution gradients, and make up the volume with H2O.

[0067] The reaction system was mixed and reacted at 37°C and 220 rpm for 30 min. After the reaction was terminated, the mixture was diluted stepwise and analyzed by HPLC. 1U was defined as the amount of enzyme required to generate 1uM ATP in 1 min under this condition.

[0068] The activity data are shown in Tables 2 and 3.

[0069] Table 2 Activity analysis

[0070]

[0071] Table 3 Difference in activity after heat treatment

[0072]

[0073] Vitality test results:

[0074] As shown in Table 2 above, the activity of the five mutation positions, ppk2-A93C, ppk2-A93T, ppk2-A93S, ppk2-I152G and ppk2-I152V, obtained by designing saturation mutations, was significantly improved. The activity of the ppk2-A93C mutation was about 31.8% higher than that of the wild type, followed by the activity of ppk2-A93T, which was 27.4% higher than that of the wild type, and the activity of ppk2-A93S was increased by 18.7%. The activity of ppk2-I152G and ppk2-I152V was also higher than that of the wild type.

[0075] By designing a heat treatment experiment, it can be seen from Table 3 that the pPK2-A93C with the highest activity can only preserve 67.1% of its own activity after heat treatment, which is lower than the 77% remaining in the wild type, and the final activity is 63.9U / mL. On the contrary, pPK2-A93T can preserve its own activity by 104% higher than the wild type, maintain 81.7% of its own activity, and the final activity is 75.2U / mL. The activity of ppk2-I152G and ppk2-I152V decreased more seriously than the wild type. Based on the above, pPK2-A93T was selected as a representative mutation for further strain transformation, and ppk2-I152V, which had a poor increase in activity, was used as a control.

[0076] Subsequent experiments have shown that the remaining mutants with increased activity can also significantly increase the amount of L-glutamine produced after enzyme conversion.

[0077] Example 7 Preparation of Corynebacterium glutamicum containing polyphosphate kinase mutant

[0078] This example uses the polyphosphate kinase mutant Ppk2-A93T as an example to illustrate the preparation of Corynebacterium glutamicum containing the polyphosphate kinase mutant. The details are as follows:

[0079] (1) Cloning genes and constructing plasmids:

[0080] The overexpression vector pXMJ19 was selected to prepare genetically engineered bacteria, and the gene encoding the polyphosphate kinase mutant ppk2-A93T or ppk2-I152V was expressed. The corresponding gene sequence was directionally cloned into the pXMJ19 expression frame by homologous recombination. The primer design is shown in Table 4.

[0081] The process of homologous recombination is as follows:

[0082] (i) Using primers 19PDF and 19PDR to obtain the target fragment by PCR:

[0083] The PCR system was 50 μL, 2xTaq mix 25 μL, 1 μL (10 pm / μL) of each of the front and back primers, 1 μL (40 μg / μL) of template DNA (ppk2-A93T or ppk2-I152V), and the remaining volume was filled with water.

[0084] The PCR program was set as follows: 95°C for 10 min, 95°C for 1 min + 55°C for 30 s + 72°C for 5 min, 30 cycles, 72°C for 1 min. The target fragment was obtained by PCR.

[0085] (ii) Using primers 19ZTF and 19ZTR, obtain the vector fragment by PCR:

[0086] The PCR system was 50 μL, 2xTaqmix 25 μL, primers 29ZTF and 29ZTR 1 μL each (10 pm / μL), corresponding mutant (pXMJ19) template DNA 1 μL (40 μg / μL), and the remaining volume was filled with water.

[0087] The PCR program was set as follows: 95°C for 10 min, 95°C for 1 min + 55°C for 30 s + 72°C for 7 min, 30 cycles, 72°C for 5 min. The vector fragment was obtained by PCR.

[0088] (iii) Take 5 μL of buffer, and the target fragment and vector fragment in a mass ratio of 1:2, mix them to obtain a total of 10 μL of homologous recombination system, and construct plasmids. After homologous recombination sequencing is correct, the successful plasmids are named pXMJ19-ppk2-A93T or pXMJ19-ppk2-I152V.

[0089] Table 4 Primer design

[0090] Primer 5’-3’ 19PDF CAGAATTAATTAAGCTTATGATTAACATTTATAAAATTG 19PDR GAGTCGACCTGCAGGCATGCTTATTTTTCAATCGGGC 19ZTF GCCCGATTGAAAAATAAGCATGCCTGCAGGTCGACTC 19ZTR CAATTTTATAAATGTTAATCATAAGCTTAATTAATTCTG

[0091] (2) Obtaining Corynebacterium glutamicum overexpressing Ppk2 enzyme (A93T):

[0092] Corynebacterium glutamicum was transformed into competent cells by chemical method, and the obtained pXMJ19-ppk2-A93T plasmid was extracted in large quantities and transformed into L-glutamine producing strain, and coated on plates (beef extract 15g / L, peptone 10g / L, yeast extract powder 5g / L, NaCl 5g / L, agar powder 20g / L, chloramphenicol 10ug / mL, pH 7.0). The culture was carried out at 37 ° C for 24-36 hours, and the resistant monoclonal strain was picked and cultured in a liquid medium (glucose 30 g / L, corn steep liquor 30 g / L, urea 3 g / L, KH2PO41 g / L, K2HPO4·3H2O 3 g / L, MgS04·7H2O 0.5 g / L, chloramphenicol 10 ug / mL, pH 7.0-7.2) to obtain Corynebacterium glutamicum capable of overexpressing Ppk2 enzyme (A93T), i.e., Corynebacterium glutamicum containing the polyphosphate kinase mutant ppk2-A93T, which was named ppk2-(A93T) overexpression strain.

[0093] The Ppk2 enzyme (A93T) in this step also can be replaced by other useful mutants to which the present invention relates.Obtain the Corynebacterium glutamicum that can overexpress the Ppk2 enzyme (I152V), i.e. contain the Corynebacterium glutamicum of polyphosphate kinase mutant ppk2-I152V, and its named after ppk2-(I152V) overexpression strain.

[0094] In other embodiments of the present invention, the expression of the ppk2 gene fragment can be episomal overexpression or genome integration.

[0095] According to the above method, the genetically engineered bacteria such as the ppk2-(A93T) overexpression strain and the ppk2-(I152V) overexpression strain prepared can be used for fermentation production of L-glutamine.

[0096] Example 8 Application of genetically engineered bacteria and fermentation production method of L-glutamine

[0097] In this example, a L-glutamine production strain (Corynebacterium glutamicum) containing wild-type polyphosphate kinase (denoted as: before transformation), a ppk2-(A93T) overexpression strain and a ppk2-(I152V) overexpression strain prepared by the method of Example 7, a total of three genetically engineered bacteria, were used to ferment and produce L-glutamine using different fermentation media and medium feeds, and the yield and the content of impurity L-glutamic acid were measured. The details are as follows:

[0098] (S1) Bacteria activation:

[0099] The corresponding strains were taken from the -80℃ refrigerator for activation. The activation medium was glucose 30g / L, corn syrup 30g / L, urea 3g / L, KH2PO41g / L, K2HPO4·3H2O 3g / L, MgS04·7H2O 0.5g / L, chloramphenicol 10ug / mL. The pH value was controlled at 7.0-7.2. The activation volume was 5mL, the inoculation amount was 1% by volume, 37℃, 200rpm, and cultured for 18h.

[0100] Seed amplification: After the seeds are activated, the same culture medium is still used to inoculate the activated seeds into a larger volume of culture medium, the volume is 300 mL, the inoculation amount is 2% by volume, 37°C, 200 rpm, and culture for 18 hours.

[0101] (S2) Fermentation culture:

[0102] Take the above-mentioned enlarged seeds for fermentation culture to produce L-glutamine. Use a 5L fermentation tank, 3L of culture medium, and an inoculation volume of 15%. After inoculation, the initial speed is 500rpm, and ammonia water is used to adjust the pH value to about 7. After 18 hours of culture, the pH value is controlled at about 6.5, and the carbon source feed is added at an appropriate flow rate. The residual sugar is controlled to maintain about 5% (by volume) for 24 hours, and then it is naturally consumed over time, and it is about 1% (by volume) at the end of fermentation. After 8 hours of culture, nitrogen source feed is added at a rate of 3mL / h. During this period, the dissolved oxygen DO is controlled at 5-10%, and the speed is coupled for adjustment. Fermentation culture is carried out for 45 hours, and samples are taken to determine the yield of L-glutamic acid and L-glutamine.

[0103] In order to compare the effects of fermentation medium formula on the production of L-glutamic acid and L-glutamine, the fermentation medium was divided into fermentation medium G1 and fermentation medium G2, and fermentation culture was carried out respectively, wherein:

[0104] ① Fermentation medium G1 contains: KH2PO4 2.5 g / L, MgSO4·7H2O 0.5 g / L, MnSO4·H2O 10 mg / L, ZnSO4·7H2O 1 mg / L, CuSO4·5H2O 1 mg / L, V B1 1mg / L, corn syrup 10g / L, glucose 140g / L. (NH4)2SO4 70g / L (needs to be sterilized separately), CaCO3 50g / L (needs to be sterilized separately). The pH value is controlled at 6.8-7.0.

[0105] ② Fermentation medium G2 contains: KH2PO4 2.5 g / L, MgSO4·7H2O 0.5 g / L, MnSO4·H2O 10 mg / L, ZnSO4·7H2O 1 mg / L, CuSO4·5H2O 1 mg / L, V B11mg / L, corn syrup 10g / L, glucose 140g / L, ATP 0.5g / L, (NaPO3) 615g / L. (NH4)2SO4 80g / L (digestion), CaCO3 50g / L (digestion). The pH value is controlled at 6.8-7.0.

[0106] In order to compare the effects of medium feed formula on the production of L-glutamic acid and L-glutamine, medium feed was also divided into two cases. The feeds corresponding to fermentation medium G1 and fermentation medium G2 were named medium feed BG1 and medium feed BG2, respectively.

[0107] ① The culture medium feed BG1 contains a nitrogen source mixed feed and a carbon source feed. The nitrogen source mixed feed contains: corn slurry 30 g / L, K2HPO4 25 g / L, MgSO4 2.5 g / L, (NH4)2SO4 100 g / L; the carbon source feed is glucose 50% (by volume).

[0108] ② The culture medium feed BG2 contains a nitrogen source mixed feed and a carbon source feed. The nitrogen source mixed feed contains: corn slurry 30 g / L, K2HPO4 25 g / L, MgSO4 2.5 g / L, (NH4)2SO4 100 g / L, ATP 0.1 g / L, (NaPO3) 6 10 g / L; the carbon source feed is glucose 50% (by volume).

[0109] The sampling results are shown in Table 5.

[0110] Table 5 L-glutamine production after fermentation of different strains

[0111]

[0112]

[0113] The above results show that the polyphosphate kinase mutant provided by the present invention has an obvious effect of improving the yield in the microbial fermentation method. When the fermentation medium G2 and the medium supplement BG2 are selected, the effect is the best. The yield in the 5L system of producing L-glutamine can reach up to 98.3g / L, and the L-glutamic acid impurities can be reduced by more than 60%, with the lowest content of 0.22%. In addition, the original strain uses the G2 fermentation medium and the corresponding supplement medium BG2, which can also achieve the purpose of partially reducing the L-glutamic acid impurities, with a reduction ratio of 6.9%. It shows that the medium formula is beneficial to ATP circulation and achieves the purpose of promoting the synthesis of L-glutamine.

[0114] In other embodiments, Corynebacterium glutamicum containing the polyphosphate kinase mutants of Examples 1-5 are used to ferment and produce L-glutamine, and the inoculation amount is 10%, 13%, 18%, 19% or 20% by volume, respectively, and the fermentation culture time is 45h, 48h, 55h, 57h or 60h, respectively. Compared with Corynebacterium glutamicum containing the wild type of polyphosphate kinase, the L-glutamine yield can be increased and the L-glutamate impurity content can be reduced.

[0115] Example 9 Method for producing L-glutamine by fermentation with genetically engineered bacteria

[0116] In this example, Corynebacterium glutamicum containing the polyphosphate kinase mutant of Example 1 was prepared for fermentation production of L-glutamine. The fermentation production process was basically the same as that of Example 8, except that the formula of the fermentation medium used in (S2) was: KH2PO4 5g / L, MgSO4·7H2O 0.2g / L, MnSO4·H2O 2mg / L, ZnSO4·7H2O 2mg / L, CuSO4·5H2O 2mg / L, V B1 2mg / L, corn syrup 5g / L, glucose 80g / L, ATP 1g / L, (NaPO3)610g / L, (NH4)2SO4100g / L and CaCO3100g / L;

[0117] The pH value is adjusted to 6.8-7.0 by ammonia water;

[0118] The nitrogen source mixed feed formula used in this embodiment is: corn steep liquor 20g / L, K2HPO4 10g / L, MgSO4 5g / L, (NH4)2SO4 150g / L, ATP 0.15g / L and (NaPO3) 65g / L;

[0119] The carbon source feed was 60% glucose by volume.

[0120] After testing, the final L-glutamine yield was 93.1 g / L, and the L-glutamic acid content was 0.37%.

[0121] Example 10 Method for producing L-glutamine by fermentation with genetically engineered bacteria

[0122] In this example, Corynebacterium glutamicum containing the polyphosphate kinase mutant of Example 1 was prepared for fermentation production of L-glutamine. The fermentation production process was basically the same as that of Example 8, except that the formula of the fermentation medium used in (S2) was: KH2PO4 1g / L, MgSO4·7H2O 1g / L, MnSO4·H2O 15mg / L, ZnSO4·7H2O 0.8mg / L, CuSO4·5H2O 0.5mg / L, V B10.5mg / L, corn syrup 20g / L, glucose 200g / L, ATP 0.1g / L, (NaPO3) 625g / L, (NH4)2SO4 40g / L and CaCO3 20g / L;

[0123] The pH value is adjusted to 6.8-7.0 by ammonia water;

[0124] The nitrogen source mixed feed formula used in this embodiment is: corn syrup 10g / L, K2HPO4 20g / L, MgSO4 1g / L, (NH4)2SO4 50g / L, ATP 0.2g / L and (NaPO3) 615g / L;

[0125] The carbon source feed was 70% glucose by volume.

[0126] After testing, the final L-glutamine yield was 87.6 g / L, and the L-glutamic acid content was 0.35%.

[0127] Example 11 Method for producing L-glutamine by fermentation with genetically engineered bacteria

[0128] In this example, Corynebacterium glutamicum containing the polyphosphate kinase mutant of Example 1 was prepared for fermentation production of L-glutamine. The fermentation production process was basically the same as that of Example 8, except that the formula of the fermentation medium used in (S2) was: KH2PO4 3g / L, MgSO4·7H2O 0.1g / L, MnSO4·H2O 20mg / L, ZnSO4·7H2O 0.1mg / L, CuSO4·5H2O 0.1mg / L, V B1 0.1mg / L, corn syrup 15g / L, glucose 160g / L, ATP 0.8g / L, (NaPO3) 65g / L, (NH4)2SO4 120g / L and CaCO3 10g / L;

[0129] The pH value is adjusted to 6.8-7.0 by ammonia water;

[0130] The nitrogen source mixed feed formula used in this embodiment is: corn syrup 50g / L, K2HPO440g / L, MgSO44g / L, (NH4)2SO4120g / L, ATP 0.01g / L and (NaPO3)68g / L;

[0131] The carbon source feed was 65% glucose by volume.

[0132] After testing, the final L-glutamine yield was 91.5 g / L and the L-glutamic acid content was 0.4%.

[0133] Example 12 Method for producing L-glutamine by fermentation with genetically engineered bacteria

[0134] In this example, Corynebacterium glutamicum containing the polyphosphate kinase mutant of Example 1 was prepared for fermentation production of L-glutamine. The fermentation production process was basically the same as that of Example 8, except that the formula of the fermentation medium used in (S2) was: KH2PO4 4g / L, MgSO4·7H2O 0.8g / L, MnSO4·H2O 8mg / L, ZnSO4·7H2O 1.6mg / L, CuSO4·5H2O 1.6mg / L, V B1 1.6mg / L, corn syrup 1g / L, glucose 100g / L, ATP 0.3g / L, (NaPO3) 620g / L, (NH4)2SO4 60g / L and CaCO3 80g / L;

[0135] The pH value is adjusted to 6.8-7.0 by ammonia water;

[0136] The nitrogen source mixed feed formula used in this embodiment is: corn slurry 40g / L, K2HPO430g / L, MgSO42g / L, (NH4)2SO480g / L, ATP 0.05g / L and (NaPO3)612g / L; the carbon source feed is 80% glucose by volume.

[0137] After testing, the final L-glutamine yield was 94.7 g / L and the L-glutamic acid content was 0.39%.

[0138] By comparing the yields, the above examples can increase the L-glutamine yield and reduce the L-glutamic acid impurity content compared to the wild-type Corynebacterium glutamicum containing polyphosphate kinase.

[0139] It should be noted that the above is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention is described in detail with reference to the above embodiments, those skilled in the art can still modify the technical solutions described in the above embodiments or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the scope of protection of the claims of the present invention.

Claims

1. A polyphosphate kinase mutant, characterized in that: Its amino acid sequence is based on the sequence shown in SEQ ID NO.1, and the 93rd alanine or the 152nd isoleucine is mutated to other amino acids.

2. The polyphosphate kinase mutant according to claim 1, characterized in that The alanine at position 93 is mutated to threonine, cysteine ​​or serine; Alternatively, the isoleucine at position 152 is mutated to glycine or valine.

3. The polyphosphate kinase mutant according to claim 1 or 2, characterized in that: When the alanine at position 93 is mutated to threonine, the amino acid sequence of the polyphosphate kinase mutant is shown in SEQ ID NO.

3.

4. A coding gene, characterized in that The coding gene encodes a gene of the polyphosphate kinase mutant according to any one of claims 1-3.

5. The gene according to claim 4, wherein the gene is expressed in an episomal manner or a genomic integrated expression manner.

6. A plasmid, characterized in that The plasmid carries the coding gene described in claims 4-5.

7. The plasmid according to claim 6, characterized in that The episomal overexpression vector is pXMJ19.

8. A genetically engineered bacterium, characterized in that: Corynebacterium glutamicum is used as a host to express the gene as described in claims 4-5.

9. An application of a genetically engineered bacterium, characterized in that: The genetically engineered bacteria described in claim 8 are used to produce L-glutamine by fermentation.

10. A fermentation production method of L-glutamine, characterized in that: The genetically engineered bacteria used for fermentation production contain the coding gene according to claim 4, and the culture medium used includes a fermentation medium and a culture medium supplement, The fermentation medium contains: KH2PO4 1-5g / L, MgSO4·7H2O 0.1-1g / L, MnSO4·H2O 2-20mg / L, ZnSO4·7H2O 0.1-2mg / L, CuSO4·5H2O 0.1-2mg / L, V B1 0.1-2mg / L, corn syrup 1-20g / L, glucose 80-200g / L, ATP 0.1-1g / L, (NaPO3) 65-25g / L, (NH4)2SO4 40-120g / L and CaCO3 10-100g / L; The pH value is adjusted to 6.8-7.0 by ammonia water; The culture medium feed contains a nitrogen source mixed feed and a carbon source feed; The nitrogen source mixed feed contains: corn slurry 10-50g / L, K2HPO4 10-40g / L, MgSO4 1-5g / L, (NH4)2SO4 50-150g / L, ATP 0.01-0.2g / L and (NaPO3)6 5-15g / L; the carbon source feed is 50-80% glucose by volume.